6-Formylindolo[3,2-b]carbazole (FICZ) Enhances The Expression of Tumor Suppressor miRNAs, miR-22, miR-515-5p, and miR-124-3p in MCF-7 Cells.
6-formylindolo[3,2-b]carbazole
Aryl Hydrocarbon Receptor
Estrogen Receptor Alpha
Tumor Suppressor miRNAs
Journal
Cell journal
ISSN: 2228-5806
Titre abrégé: Cell J
Pays: Iran
ID NLM: 101566618
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
18
11
2018
accepted:
21
02
2019
entrez:
14
10
2019
pubmed:
14
10
2019
medline:
14
10
2019
Statut:
ppublish
Résumé
microRNAs (miRNAs) play bifunctional roles in the initiation and progression of cancer, and recent evidence has confirmed that unusual expression of miRNAs is required for the progress of breast cancer. The regulatory role of aryl hydrocarbon receptor (AhR) and its endogenous ligand, 6-formylindolo[3,2-b]carbazole (FICZ) on the expression of tumor suppressor miRNAs, miR-22, miR-515-5p and miR-124-3p, as well as their association with the estrogen receptor alpha (ERα) were the aims of this study. In this experimental study, the expression levels of Our results revealed that Overall, our data demonstrated that FICZ, as an AhR agonist could induce the expression of tumor suppressor miRNAs,
Identifiants
pubmed: 31606975
doi: 10.22074/cellj.2020.6549
pmc: PMC6791069
doi:
Types de publication
Journal Article
Langues
eng
Pagination
115-120Informations de copyright
Copyright© by Royan Institute. All rights reserved.
Déclaration de conflit d'intérêts
There is no conflict of interest in this study.
Références
J Biol Chem. 2005 Jun 3;280(22):21607-11
pubmed: 15837795
J Biochem Mol Toxicol. 2018 Jul 5;:e22164
pubmed: 29975444
Chem Res Toxicol. 2015 Dec 21;28(12):2278-86
pubmed: 26535918
Nat Rev Cancer. 2006 Dec;6(12):947-60
pubmed: 17128211
Mol Endocrinol. 2003 Oct;17(10):2002-12
pubmed: 12881510
Oncogene. 2016 May;35(21):2766-76
pubmed: 26477310
Exp Ther Med. 2017 Aug;14(2):1009-1016
pubmed: 28781618
Cancer Res. 2014 Jul 15;74(14):3764-78
pubmed: 24906624
BMC Cancer. 2016 Nov 15;16(1):826
pubmed: 27842510
Mol Cell Biol. 2009 Jul;29(13):3783-90
pubmed: 19414598
Biol Res. 2017 Sep 7;50(1):27
pubmed: 28882183
Carcinogenesis. 2013 Mar;34(3):713-22
pubmed: 23250910
J Pharmacol Exp Ther. 2015 Sep;354(3):417-25
pubmed: 26163549
Tumour Biol. 2015 Aug;36(8):5987-97
pubmed: 25731732
Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):4479-84
pubmed: 22392998
Cancer Biol Ther. 2015;16(5):714-23
pubmed: 25996841
Expert Opin Ther Pat. 2015;25(9):953-70
pubmed: 26161698
Mol Endocrinol. 2008 Feb;22(2):304-16
pubmed: 17991765
Am J Transl Res. 2018 Mar 15;10(3):659-669
pubmed: 29636857
PLoS One. 2015 Jun 26;10(6):e0128472
pubmed: 26115122
Cell Physiol Biochem. 2013;31(6):823-32
pubmed: 23816858
Curr Drug Targets. 2010 Sep;11(9):1059-73
pubmed: 20545613
Mol Cell. 2009 Oct 23;36(2):340-7
pubmed: 19854141
Arch Toxicol. 2017 Oct;91(10):3365-3372
pubmed: 28289825
Oncotarget. 2015 Aug 14;6(23):19721-34
pubmed: 26254224
PLoS One. 2008;3(10):e3420
pubmed: 18923704
Biomed Rep. 2015 May;3(3):309-312
pubmed: 26137228
CA Cancer J Clin. 2014 Jan-Feb;64(1):52-62
pubmed: 24114568
FEBS J. 2010 Apr;277(7):1684-94
pubmed: 20180843
Oncotarget. 2017 Apr 4;8(14):22443-22459
pubmed: 27705918
Chem Biol Interact. 2016 May 25;252:19-27
pubmed: 27041069
Chem Res Toxicol. 2012 Sep 17;25(9):1878-84
pubmed: 22867086
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
J Hematol Oncol. 2015 Aug 13;8:98
pubmed: 26264704
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
J Biol Chem. 2009 Jan 30;284(5):2690-6
pubmed: 19054769
J Pharm Sci. 2017 Aug;106(8):2152-2162
pubmed: 28479355
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
EMBO Rep. 2016 Apr;17(4):570-84
pubmed: 26882547
Nucl Recept Signal. 2006;4:e016
pubmed: 16862222